HER-2 NEGATIVE BREAST CANCER MARKET ANALYSIS
Global HER-2 Negative Breast Cancer Market: Key Developments
In September 2022, Gilead Sciences Inc. reported new data from a posthoc subgroup analysis of Phase III TROPiCS-02 study comparing Trodelvy (sacituzumab govitecan-hziy) with comparator chemotherapies in patients with HR+/HER2- metastatic breast cancer who progressed on at least two chemotherapies and endocrine-based therapies.
In August 2022, the FDA approved Enhertu, a radiation therapy targeted to patients with HER2-low breast cancer subtype, which is a newly defined subset of HER2-negative breast cancer.
In March 2022, AstraZeneca and MSD's Lynparza (Olaparib) was approved in the United States for the adjuvant treatment of patients with germline BRCA-mutated HER2-negative high-risk early breast cancer who have already undergone chemotherapy either before or after surgery.
In November 2021, Olema Pharmaceuticals Inc. reported the first clinical data from the Phase 1 dose-escalation portion of the ongoing Phase 1/2 clinical trial of OP-1250, the complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) in development for the treatment of HER2-negative breast cancer and other women’s cancers.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India :